Nurix Therapeutics, Inc.
NRIX
$12.46
$0.201.59%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
11/5/2025
-
MarketBeat
11/5/2025
-
MarketBeat
11/5/2025
-
MarketBeat
Why Nurix Therapeutics (NRIX) Is Up 5.3% After Advancing Bexobrutideg Trial and Raising $250 Million
11/4/2025
-
Simply Wall St
11/4/2025
-
Tickeron - Stocks
11/4/2025
-
Benzinga
11/4/2025
-
GuruFocus
11/4/2025
-
MarketBeat
11/4/2025
-
GuruFocus
11/3/2025
-
GuruFocus
11/3/2025
-
Globe Newswire
10/31/2025
-
MarketBeat
10/31/2025
-
MarketBeat
10/31/2025
-
Tickeron - Stocks
10/31/2025
-
Tickeron - Stocks
10/30/2025
-
GuruFocus
10/30/2025
-
Globe Newswire
10/30/2025
-
Tickeron - Stocks
10/29/2025
-
MarketBeat
10/29/2025
-
MarketBeat
10/28/2025
-
MarketBeat
10/28/2025
-
Market News Video
10/28/2025
-
The Fly
10/28/2025
-
Tickeron - Stocks
10/28/2025
-
Tickeron - Stocks
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, October 9, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Jan 26 and 30 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
415 660 5320
Address
1700 Owens Street
San Francisco, CA 94158
San Francisco, CA 94158
Country
Year Founded
Business Description
Sector
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of...
more